



# Congressman **Tom Lantos**

**12<sup>TH</sup> CONGRESSIONAL DISTRICT OF CALIFORNIA**  
**(San Mateo County / San Francisco)**

---

**FOR IMMEDIATE RELEASE**  
**September 9, 2003**

**FOR INFORMATION CALL:**  
**Bob King- (202) 225-6735**

---

## **TOM LANTOS ANNOUNCES \$2 MILLION TECHNOLOGY GRANT TO SOUTH SAN FRANCISCO BIO-TECH FIRM, GRYPHON**

Congressman Tom Lantos (D-San Mateo County/San Francisco) announced the award of a \$2 million three-year Advanced Technology Program (ATP) grant to Gryphon Therapeutics of South San Francisco. ATP grants are awarded by the federal government's National Institute of Standards and Technology (NIST) and are designed to benefit the U.S. economy by sharing the costs of research with industry to foster new, innovative technologies.

"This award is additional proof that the Peninsula, as well as the entire the Bay area, continues to anchor our nation's bio-technology industry," Congressman Lantos said in announcing the award. "Through these grants, American companies are able to engage in research and development of new products with limitless potential to improve the lives of all Americans."

The ATP grants bridge the gap between the laboratory and the market place through research partnerships with the private sector. ATP provides funding on a cost-share basis to companies in order to accelerate the development and broad dissemination of challenging, high-risk technologies that promise significant commercial payoffs and widespread benefits for the nation.

This particular project will last for three years. The NIST has committed to provide a total of \$2 million over the next three years (October 1, 2003 through September 30, 2006). Gryphon will provide \$1,247,869 over that same three-year period. In the first year, the federal government will provide funding of \$643,460.

ATP awards are made on the basis of a rigorously competitive peer review process considering the scientific as well as the technological merit of each proposal as well as its potential for broad-based economic benefits to the United States. By reducing the early-stage research and development (R&D) risks for individual companies, the ATP grant enables industry to pursue promising technologies which otherwise would be ignored or developed too slowly to compete in rapidly changing world markets.

— # # # —